Category: drug discovery
Journey Clinical raises $3M to allow psychotherapists to prescribe psychedelics
Psychedelics companies are all the rage right now. Compass Pathways is working with the magic mushroom compound psilocybin to treat depression. It’s has raised $290 million in total. Atai Life Sciences — backed by PayPal co-founder Peter Thiel — brought in $258 million from its IPO. In the tech space,…
Read More
Longevity startup Gero AI has a mobile API for quantifying health changes
Sensor data from smartphones and wearables can meaningfully predict an individual’s ‘biological age’ and resilience to stress, according to Gero AI. The ‘longevity’ startup — which condenses its mission to the pithy goal of “hacking complex diseases and aging with Gero AI” — has developed an AI model to predict…
Read More
K Health expands into virtual childcare and raises $132 million at a $1.5 billion valuation
K Health, the virtual health care provider that uses machine learning to lower the cost of care by providing the bulk of the company’s health assessments, is launching new tools for childcare on the heels of raising cash that values the company at $1.5 billion. The $132 million round raised…
Read More
Genesis Therapeutics raises $52M A round for its AI-focused drug discovery mission
Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Genesis Therapeutics has a new simulation approach and cross-disciplinary team that has clearly made an impression: the company just raised…
Read More
Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery
Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the pharmaceuticals industry turns its attention to precision medicine — the search for ever more tailored treatments for specific…
Read More
Potential new treatment for COVID-19 uncovered by BenevolentAI enters trials
BenevolentAI, a startup which has raised $292 million to apply AI to create drugs faster, today says it has uncovered an already approved drug as a potential treatment for COVID-19, after it applied its AI platform and team to the problem. The revelation, which has now appeared in peer-reviewed scientific…
Read More